drugset / Trial / NCT06385236

Summary

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.

Timeline

Start
2024-02-19
Primary completion
2027-06-30
Completion
2028-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Benralizumab Monoclonal antibody 30 mg Subcutaneous
Comparator Dupilumab Monoclonal antibody 300 mg Subcutaneous

Indications